----

UNITED STATES 

| NEVADA                                                         | 98-0559606                          |
|----------------------------------------------------------------|-------------------------------------|
| (State or other jurisdiction of incorporation or organization) | (I.R.S Employer Identification No.) |
|                                                           |                                |
| 1365 N. Courtenay Parkway, Suite A                             |                                |
| Merritt Island, FL                                             | 32953                               |
| (Address of principal executive offices)                       | (Zip Code)                     |

|                     Large accelerated filer [  ]                | Accelerated filer                                             [  ] |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                     Non-accelerated filer   [  ] | Smaller reporting company                           [x]                                                                                                           |

----

PART I - FINANCIAL INFORMATION 

| ITEM 1. | FINANCIAL STATEMENTS. |
|---------|-----------------------|

----

| THERABIOGEN, INC. |
|-------------------|
| BALANCE SHEETS    |

|                                                                                                                     |   | November 30,                    |   |   | February 28, |   |
|--------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|--------|--------|--------------|--------|
|                                                                                                                     |   | 2009                            |   |   | 2009         |   |
|                                                                                                                     |   | (unaudited)                     |   |   |         |   |
|                                                                                                                     |   |                            |   |   |         |   |
| ASSETS                                                                                                                   |   |                            |   |   |         |   |
| Current assets:                                                                                                          |   |                            |   |   |         |   |
|      Cash                                                                                                 | $      |  1                         |   | $      |  70     |   |
|                                                                                                                     |   |                            |   |   |         |   |
|      Total assets                                                                                         | $      |  1                         |   | $      |  70     |   |
|                                                                                                                     |   |                            |   |   |         |   |
| LIABILITIES AND STOCKHOLDERS' DEFICIT                                                                                    |   |                            |   |   |         |   |
| Current liabilities:                                                                                                     |   |                            |   |   |         |   |
|      Accounts payable                                                                                     | $      |  47,378                    |   | $      |  42,558 |   |
|      Accrued administrative fees                                                                          |   |     -       |   |   | 3,150        |   |
|      Advances payable                                                                                |   |      - |   |   | 27,365       |   |
|      Due to related party                                                                                 |   |     -       |   |   | 381          |   |
|                                                                                                                     |   |                            |   |   |         |   |
|      Total liabilities                                                                                    |   | 47,378                          |   |   | 73,454       |   |
| Commitments and contingencies                                                                                            |   |                            |   |   |         |   |
| Stockholders' deficit:                                                                                                   |   |                            |   |   |         |   |
|      Common stock; authorized 75,000,000; $0.001 par value; 5,230,000                                     |   |                            |   |   |         |   |
|                issued and outstanding at November 30, 2009 and February 28, 2009 |   | 5,230                           |   |   | 5,230        |   |
|      Additional paid in capital                                                                           |   | 51,270                          |   |   | 51,270       |   |
|      Deficit accumulated during the exploration stage                                                     |   | (103,877                        | )      |   | (129,884     | )      |
|                                                                                                                     |   |                            |   |   |         |   |
|      Total stockholders' deficit                                                                          |   | (47,377                         | )      |   | (73,384      | )      |
|                                                                                                                     |   |                            |   |   |         |   |
|      Total liabilities and stockholders' deficit                                                          | $      |  1                         |   | $      |  70     |   |

----

| THERABIOGEN, INC.        |
|--------------------------|
| STATEMENTS OF OPERATIONS |
| (UNAUDITED)              |

|                                                                    |   |                                                                |   |          |                                                                                              |    |    | From                              |   |
|-------------------------------------------------------------------------|--------|---------------------------------------------------------------------|--------|---------------|---------------------------------------------------------------------------------------------------|---------|---------|-----------------------------------|--------|
|                                                                    |   | Three Months Ended                                                  |   |          | October 3, 2005                                                                                   |    |
|                                                                    |   | November 30,                                                        |   |          | November 30,                                                                                      |    |    | (Inception) to                    |   |
|                                                                    |   | 2009                                                                |   |          | 2008                                                                                              |    |    | November 30, 2009                 |   |
|  Income:     Income from debt forgiveness | $      |            - |   |  $       |                 - |    |  $ |   45,320                     |   |
|                                                                    |   |                                                                |   |          |                                                                                              |    |    |                              |   |
|                                                                    |   |                                                                |   |          |                                                                                              |    |    |                              |   |
| Operating Expenses:                                                     |   |                                                                |   |          |                                                                                              |    |    |                              |   |
|                                                                    |   |                                                                |   |          |                                                                                              |    |    |                              |   |
|      Administrative fees                                 | $      |      -                                     |   |   $ |          3,130                                       |    | $       |  18,850                      |   |
|      Bank charges and interest                           |   |  -                                                             |   |          |            256                             |    |    |      945 |   |
|      Donated rent                                        |   | -                                                                   |   |          | -                                                                                                 |    |    | 4,000                             |   |
|      Donated services                                    |   | -                                                                   |   |          | -                                                                                                 |    |    | 8,000                             |   |
|      Exploration and development costs                   |   | -                                                                   |   |          |      -                                                                   |    |    | 21,240                            |   |
|      Foreign exchange gains and losses              |   |    -                                                 |   |          | -                                                                                                 |    |    | 598                               |   |
|                                                                    |   |                                                                |   |          |                                                                                              |    |    |                              |   |
|      Professional fees                              |   |     -                                           |   |          | 6,411                                                                                             |    |    | 89,439                            |   |
|      Office                                         |   |   -                                                       |   |          | -                                                                                                 |    |    | 155                               |   |
|                                                                    |   |                                                                |   |          |                                                                                              |    |    |                              |   |
|      Regulatory expenses                                 |   |                                                                |   |          |   496                                                                                   |    |    | 5,970                             |   |
|                                                                    |   |                                                                |   |          |                                                                                              |    |    |                              |   |
|      Net income (loss)                                   | $      |       -                               |   |   $ | (10,293                                                                                           |  ) | $       |  (103,877)                   |   |
|                                                                    |   |                                                                |   |          |                                                                                              |    |    |                              |   |
| Net income (loss) per share:                                            |   |                                                                |   |          |                                                                                              |    |    |                              |   |
|      Basic and diluted                                   |   |  0.00                                                          |   |          | (0.00                                                                                             | )       |    |                              |   |
|                                                                    |   |                                                                |   |          |                                                                                              |    |    |                              |   |
| Weighted average number of shares outstanding:                          |   |                                                                |   |          |                                                                                              |    |    |                              |   |
|      Basic and diluted                                   |   | 5,230,000                                                           |   |          | 5,230,000                                                                                         |    |    |                              |   |

----

| THERABIOGEN INC.               |
|--------------------------------|
| (AN EXPLORATION STAGE COMPANY) |
| STATEMENTS OF OPERATIONS       |
| (UNAUDITED)                    |

|                                                                          |   |                                       |   |          |                                                                                              |    |    | From                              |   |
|-------------------------------------------------------------------------------|--------|--------------------------------------------|--------|---------------|---------------------------------------------------------------------------------------------------|---------|---------|-----------------------------------|--------|
|                                                                          |   | Nine Months Ended                          |   |          | October 3, 2005                                                                                   |    |
|                                                                          |   | November 30,                               |   |          | November 30,                                                                                      |    |    | (Inception) to                    |   |
|                                                                          |   | 2009                                       |   |          | 2008                                                                                              |    |    | November 30, 2009                 |   |
|  Income:     Income from debt forgiveness  | $      |       45,230 |   |  $       |                 - |    |  $ |   45,230                     |   |
|                                                                          |   |                                       |   |          |                                                                                              |    |    |                              |   |
|                                                                          |   |                                       |   |          |                                                                                              |    |    |                              |   |
| Operating Expenses:                                                           |   |                                       |   |          |                                                                                              |    |    |                              |   |
|                                                                          |   |                                       |   |          |                                                                                              |    |    |                              |   |
|      Administrative fees                                       | $      |      3,000        |   |   $ |          5,250                                       |    | $       |  18,850                      |   |
|      Bank charges and interest                                 |   |  78                                   |   |          |             262                       |    |    |      945 |   |
|      Donated rent                                              |   | -                                          |   |          | -                                                                                                 |    |    | 4,000                             |   |
|      Donated services                                          |   | -                                          |   |          | -                                                                                                 |    |    | 8,000                             |   |
|      Exploration and development costs                         |   | -                                          |   |          |      12,452                                                              |    |    | 21,240                            |   |
|      Foreign exchange gains and losses                    |   |   1,201                          |   |          | -                                                                                                 |    |    | 598                               |   |
|                                                                          |   |                                       |   |          |                                                                                              |    |    |                              |   |
|      Professional fees                                    |   |    14,902                   |   |          | 24,930                                                                                            |    |    | 89,439                            |   |
|      Office                                               |   |   -                              |   |          | -                                                                                                 |    |    | 155                               |   |
|                                                                          |   |                                       |   |          |                                                                                              |    |    |                              |   |
|      Regulatory                                                |   | 50-                                        |   |          | 2,109                                                                                             |    |    | 5,970                             |   |
|                                                                          |   |                                       |   |          |                                                                                              |    |    |                              |   |
|      Net income (loss)                                         | $      |  26,007                               |   |   $ | (45,003                                                                                           |  ) | $       |  (103,877)                   |   |
|                                                                          |   |                                       |   |          |                                                                                              |    |    |                              |   |
| Net income (loss) per share:                                                  |   |                                       |   |          |                                                                                              |    |    |                              |   |
|      Basic and diluted                                         |   |  0.00                                 |   |          | (0.01                                                                                             | )       |    |                              |   |
|                                                                          |   |                                       |   |          |                                                                                              |    |    |                              |   |
| Weighted average number of shares outstanding:                                |   |                                       |   |          |                                                                                              |    |    |                              |   |
|      Basic and diluted                                         |   | 5,230,000                                  |   |          | 5,230,000                                                                                         |    |    |                              |   |

----

| THERABIOGEN INC.               |
|--------------------------------|
| (AN EXPLORATION STAGE COMPANY) |
| STATEMENTS OF CASH FLOWS       |
| UNAUDITED                      |

|                                                                                                                                  |   |                                                                         |    |   |                |   |   | From                                 |   |
|---------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------------------------------------|---------|--------|---------------------|--------|--------|--------------------------------------|--------|
|                                                                                                                                  |   |                                                                         |    |   |                |   |   | October 3, 2005                      |   |
|                                                                                                                                  |   | Nine Months Ended                                                            |    |   | (Inception)         |   |
|                                                                                                                                  |   | November 30,                                                                 |    |   | November 30,        |   |   | to November 30,                      |   |
|                                                                                                                                  |   | 2009                                                                         |    |   | 2008                |   |   | 2009                                 |   |
|                                                                                                                                  |   |                                                                         |    |   |                |   |   |                                 |   |
| Cash flow from operating activities:                                                                                                  |   |                                                                         |    |   |                |   |   |                                 |   |
|      Net loss                                                                                                          | $      |  26,007                                                                 |    | $      |  (45,003       | )      | $      |  (103,877                       | )      |
|                  Adjustments to reconcile net loss to net cash                           |   |                                                                         |    |   |                |   |   |                                 |   |
|                              used in operating activities: |   |                                                                         |    |   |                |   |   |                                 |   |
|                  Donated rent and services                                               |   | -                                                                            |    |   | -                   |   |   |      12,000 |   |
|                  Changes in operating assets and liabilities:                            |   |                                                                         |    |   |                |   |   |                                 |   |
|                        Accounts payable                                   |   |  2,170                                                                  |    |   | 23,629              |   |   | 47,378                               |   |
|                        Accrued administrative fees                        |   |    -                                                          |    |   | 5,250               |   |   |     -            |   |
|                        Accrued professional fees                          |   | -                                                                            |    |   | (7,159              | )      |   |     -            |   |
|                        Advances payable                                   |   |   -                                                                |    |   | -                   |   |   |      -      |   |
|                        Due to related party                               |   | (28,246                                                                      |  ) |   | 21,367              |   |   |  (500                           | )      |
|                                                                                                                                  |   |                                                                         |    |   |                |   |   |                                 |   |
|      Net cash provided by (used in) operating activities                                                               |   | (69)                                                                         |    |   | (1,916              | )      |   | (40,219                              | )      |
|                                                                                                                                  |   |                                                                         |    |   |                |   |   |                                 |   |
| Cash flows from financing activities                                                                                                  |   |                                                                         |    |   |                |   |   |                                 |   |
|      Cash from issuance of common stock                                                                                |   | -                                                                            |    |   | -                   |   |   | 40,750                               |   |
|                                                                                                                                  |   |                                                                         |    |   |                |   |   |                                 |   |
|      Net cash provided by financing activities                                                                         |   | -                                                                            |    |   | -                   |   |   | 40,750                               |   |
|                                                                                                                                  |   |                                                                         |    |   |                |   |   |                                 |   |
| Increase (decrease) in cash during the period                                                                                         |   |             (69) |    |   | (1,916              | )      |   | 531                                  |   |
|                                                                                                                                  |   |                                                                         |    |   |                |   |   |                                 |   |
| Cash, beginning of period                                                                                                             |   | 70                                                                           |    |   | 1,916               |   |   | -                                    |   |
|                                                                                                                                  |   |                                                                         |    |   |                |   |   |                                 |   |
| Cash, end of period                                                                                                                   | $      |  1                                                                      |    | $      |    - |   | $      |  531                            |   |
|                                                                                                                                  |   |                                                                         |    |   |                |   |   |                                 |   |
| Supplemental disclosure of cash flow information:                                                                                     |   |                                                                         |    |   |                |   |   |                                 |   |
|      Cash paid during the period                                                                                       |   |                                                                         |    |   |                |   |   |                                 |   |
|                  Taxes                                                                   | $      |  -                                                                      |    | $      |  -             |   | $      |  -                              |   |
|                  Interest                                                                | $      |  -                                                                      |    | $      |  -             |   | $      |  -                              |   |

----

| THERABIOGEN INC.                  |
|-----------------------------------|
| (AN EXPLORATION STAGE COMPANY)    |
| NOTES TO THE FINANCIAL STATEMENTS |
| NOVEMBER 30, 2009                 |
| (Unaudited)                       |

----

| THERABIOGEN INC.                  |
|-----------------------------------|
| (AN EXPLORATION STAGE COMPANY)    |
| NOTES TO THE FINANCIAL STATEMENTS |
| NOVEMBER 30, 2009                 |
| (Unaudited)                       |

----

| THERABIOGEN INC.                  |
|-----------------------------------|
| (AN EXPLORATION STAGE COMPANY)    |
| NOTES TO THE FINANCIAL STATEMENTS |
| NOVEMBER 30, 2009                 |
| (Unaudited)                       |

----

| THERABIOGEN INC.                  |
|-----------------------------------|
| (AN EXPLORATION STAGE COMPANY)    |
| NOTES TO THE FINANCIAL STATEMENTS |
| NOVEMBER 30, 2009                 |
| (Unaudited)                       |

----

| THERABIOGEN INC.                  |
|-----------------------------------|
| (AN EXPLORATION STAGE COMPANY)    |
| NOTES TO THE FINANCIAL STATEMENTS |
| NOVEMBER 30, 2009                 |
| (Unaudited)                       |

----

| THERABIOGEN INC.                  |
|-----------------------------------|
| (AN EXPLORATION STAGE COMPANY)    |
| NOTES TO THE FINANCIAL STATEMENTS |
| NOVEMBER 30, 2009                 |
| (Unaudited)                       |

----

| THERABIOGEN INC.                  |
|-----------------------------------|
| (AN EXPLORATION STAGE COMPANY)    |
| NOTES TO THE FINANCIAL STATEMENTS |
| NOVEMBER 30, 2009                 |
| (Unaudited)                       |

| Shareholder                                                 |   | Shares     |   | Percent |
|-------------------------------------------------------------|--------|------------|--------|---------|
| Common shares held by former TheraBiogen, Inc. shareholders |   | 19,091,000 |   | 58.4    |
| Common shares held by Kushi Resources, Inc. shareholders    |   | 13,598,000 |   | 41.6    |
| Total post-merger shares                                    |   | 32,689,000 |   | 100.0   |

----

| ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ANDRESULTS OF OPERATIONS. |
|---------|---------------------------------------------------------------------------------------------|

----

| Phase                 | Exploration Program                                                       | Approximate Cost*             | Status                                                                                                                               |
|-----------------------|---------------------------------------------------------------------------|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| One    | Prospecting, Trenchingand Sampling andHelicopter-SupportedMagnetic Survey | $22,000        | Completed Helicopter-Supported Magnetic Surveyat a cost of $11,648. Thebalance of this phase isexpected to be completed inJune 2010. |
| Two                   | Coverage of the areawith VLF-EM andmagnetometer surveys                   | between $55,000 and $130,000  | Dependent upon the results ofPhase One.                                                                                              |
| Three                 | Geological mapping andsampling                                            | between $175,000 and $215,000 | Dependent upon the results ofPhase Two.                                                                                              |
|                  | Total Estimated Cost                                                      | between $250,000 and $365,000 |                                                                                                                                 |

| Category                                | Planned Expenditures Over The Next 12 Months (US$) |
|-----------------------------------------|----------------------------------------------------|
| Legal and Accounting Fees               | $47,200                                            |
| Regulatory and Other Operating Expenses | $7,000                                             |
| Mineral Property Exploration Expenses   | $12,150                                            |
| TOTAL                                   | $66,350                                            |

----

----

| Three Months Summary |   |                                  |   |   |              |   |
|----------------------|--------|---------------------------------------|--------|--------|-------------------|--------|
|                 |   | Three Months                          |   |   | Three Months      |   |
|                 |   | Ended                                 |   |   | Ended             |   |
|                 |   | November 30, 2009                     |   |   | November 30, 2008 |   |
| Revenue              | $      |      -       |   | $      |  -           |   |
| Expenses             |   |    -                   | )      |   | (7,255            | )      |
| Net Gain (Loss)      | $      |       - |   | $      |  (27,455     | )      |

----

|                      |         | Three Months                    |   |   | Three Months      |   |
|---------------------------|--------------|---------------------------------|--------|--------|-------------------|--------|
|                      |         | Ended                           |   |   | Ended             |   |
|                      |         | November 30, 2009               |   |   | November 30, 2008 |   |
| Administrative Fees       | $            |      - |   | $      |  3,130       |   |
| Bank Charges and Interest |         |  -                         |   |   | 256               |   |
| Office                    |         |  -                         |   |   | -                 |   |
| Professional Fees         |    |      - |   |   | 6,411             |   |
| Regulatory                |         |  -                         |   |   | 496               |   |
| Total Operating Expenses  | $            |    -             |   | $      | 10,293            |   |

| Nine Months Summary |   |              |   |   |              |   |
|---------------------|--------|-------------------|--------|--------|-------------------|--------|
|                |   | Nine Months       |   |   | Nine Months       |   |
|                |   | Ended             |   |   | Ended             |   |
|                |   | November 30, 2009 |   |   | November 30, 2008 |   |
| Revenue             | $      | 45,320            |   | $      |  -           |   |
| Expenses            |   | (19,313           | )      |   | (45,003           | )      |
| Net Gain (Loss)     | $      |   26,007     |   | $      |  (34,710     | )      |

|                        |   | Nine Months       |   |   | Nine Months       |   |   |   |
|-----------------------------|--------|-------------------|--------|--------|-------------------|--------|--------|--------|
|                        |   | Ended             |   |   | Ended             |   |   |   |
|                        |   | November 30, 2009 |   |   | November 30, 2008 |   |   |   |
| Administrative Fees         | $      |  3,000       |   | $      | 5,250             |   |   |   |
| Bank Charges and Interest   |   | 100               |   |   |  262         |   |   |   |
| Exploration and Development |   | -                 |   |   | 12,452            |   |   |   |
| Office                      |   | 60                |   |   | -                 |   |   |   |
| Professional Fees           |   | 16,103            |   |   | 24,930            |   |   |   |
|                        |   |              |   |   |              |   |   |   |
|                        |   |              |   |   |              |   |   |   |
| Regulatory                  |   | 50                |   |   | 2,109             |   |   |   |
| Total Operating Expenses    | $      |  19,313      |   | $      | 45,003            |   |   |   |

----

|  Working Capital             |   |              |   |   |              |   |   |       |   |
|-----------------------------------|--------|-------------------|--------|--------|-------------------|--------|--------|------------|--------|
|                              |   |              |   |   |              |   |   | Percentage |   |
|                              |   | At                |   |   | At                |   |   | Increase / |   |
|                              |   | November 30, 2009 |   |   | February 28, 2009 |   |   | (Decrease) |   |
| Current Assets                    | $      |  1           |   | $      |  70          |   |   | 658.6%     |   |
| Current Liabilities               |   | (47,378           | )      |   | (73,454           | )      |   | (35.5)%    |   |
| Working Capital Surplus (Deficit) | $      |  (47,377     | )      | $      |  (73,384     | )      |   | (36.2)%    |   |

| Cash Flows                                            |   |                           |   |   |         |   |
|-------------------------------------------------------|--------|--------------------------------|--------|--------|--------------|--------|
|                                                  |   | Nine Months Ended November 30, |   |
|                                                  |   | 2009                           |   |   | 2008         |   |
| Cash Flows Provided by (Used In) Operating Activities | $      |  (69)                     |   | $      |  (1,916 | )      |
| Cash Flows (Used In) Investing Activities             |   | -                              |   |   | -            |   |
| Cash Flows From Financing Activities                  |   | -                              |   |   | -            |   |
| Net Increase (Decrease) In Cash During Period         | $      |  (69)                     |   | $      |  (1,916 | )      |

----

costs for impairment under SFAS No. 144, Accounting for Impairment or Disposal of Long Lived Assets at each fiscal quarter end. An impairmentis recognized when the sum of the expected undiscounted future cash flows is less than the carrying amount of the mineral property. Impairment losses, if any, are measured as the excess of the carrying amount of the mineral property over its estimated fair value.  When it has been determined that a mineral property can be economically developed as a result of establishing proven and probable reserves, the costs then incurred to develop such property, are capitalized. Such costs will be amortized usingthe units-of-production method over the estimated life of the probable reserves. If mineral properties are subsequently abandoned or impaired, any capitalized costs will be charged to operations. 

| ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.  |
|---------|-------------------------------------------------------------------|

| ITEM 4T. | CONTROLS AND PROCEDURES.  |
|----------|--------------------------------|

----

| ITEM 1. | LEGAL PROCEEDINGS.  |
|---------|--------------------------|

| ITEM 1A. | RISK FACTORS.  |
|----------|---------------------|

| ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.  |
|---------|--------------------------------------------------------------------|

| ITEM 3. | DEFAULTS UPON SENIOR SECURITIES.  |
|---------|----------------------------------------|

| ITEM 4. | SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.  |
|---------|------------------------------------------------------------|

| ITEM 5. | OTHER INFORMATION.  |
|---------|--------------------------|

----

|   | PRO FORMA CONSOLIDATED BALANCE SHEET |   |
|--------|--------------------------------------|--------|
|   | FEBRUARY 28, 2009                    |   |
|   | (Unaudited)                          |   |

|                                       |   | KUSHI RESOURCES |   | THERABIOGEN |   | CONSOLIDATED |
|--------------------------------------------|--------|-----------------|--------|-------------|--------|--------------|
| ASSETS                                     |   |            |   |        |   |         |
| Current assets                             |   |            |   |        |   |         |
| Cash                                       | $      | 70              | $      | 871         | $      | 941          |
| Other current assets                       |   |            |   |        |   |         |
|                                       |   |            |   |        |   |         |
| License, net of amortization               |   | 0               |   | 2,313,9980  |   | 2,313,980    |
| Total current assets                       |   | 70              |   | 2,313,9980  |   | 2,313,980    |
| TOTAL ASSETS                          | $      | 70              | $      | 2,313,9980  | $      | 2,313,980    |
|                                       |   |            |   |        |   |         |
| LIABILITIES AND SHAREHOLDERS' EQUITY       |   |            |   |        |   |         |
| Current liabilities                        |   |            |   |        |   |         |
| Accounts payable and other                 |   | 73,454          |   | 20,275      |   | 93,729       |
| Other current liabilities                  |   |            |   |        |   |         |
| Accrued interest                           |   | 0               |   | 8,135       |   | 8,135        |
| Notes payable                              |   | 0               |   | 249,500     |   | 249,500      |
| Total current liabilities                  |   | 73,454          |   | 277,910     |   | 351,364      |
| Long-term liabilities                      |   | 0               |   | 0           |   | 0            |
| TOTAL LIABILITIES                          |   | 73,454          |   | 277,910     |   | 351,364      |
| Shareholders' equity (deficit)             |   |            |   |        |   |         |
| Common stock                               | $      | 5,230           | $      | 1,880       | $      | 32,389       |
| Additional paid-in capital                 |   | 51,270          |   | 2,225,315   |   | 2,251,306    |
| Accumulated deficit                        |   | (129,884)       |   | (190,254)   |   | (320,138)    |
| SHAREHOLDER'S EQUITY (DEFICIT)             |   | (73,384)        |   | 2,036,941   |   | 1,963,557    |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY |   | 70              |   | 2,314,851   |   | 2,314,921    |

| Kushi Resources | TheraBiogen |
|-----------------|-------------|

|                       |   | Pre-split |   | Post-split |   | Pre-merger |   | Post-merger |   | Consolidated |
|----------------------------|--------|-----------|--------|------------|--------|------------|--------|-------------|--------|--------------|
| Common Stock               |   | 5,230     |   | 13,598     |   | 1,880      |   | 18,791      |   | 32,389       |
| Additional paid-in capital |   | 51,270    |   | 42,902     |   | 2,225,315  |   | 2,208,404   |   | 2,251,306    |
| Accumulated deficit        |   | (129,884) |   | (129,884)  |   | (190,254)  |   | (190,254)   |   | (320,138)    |
| Shareholders' deficit      |   | (73,384)  |   | (73,384)   |   | 2,036,941  |   | 2,036,941   |   | 2,314,921    |

----

|                        | Kushi Resources |     | TheraBiogen | Consolidated |
|-----------------------------|-----------------|----------|-------------|--------------|
| Income                      | $               | 0        | $           | 0            | $ | 0 |
| Expenses:                   |            |     |        |         |   |   |
| Amortization                |            | 0        |        | 39,220       |   | 39,220 |
| Bank fees                   |            | 337      |        | 210          |   | 547 |
| Consulting                  |            | 8,400    |        | 79,040       |   | 87,440 |
| Exploration expenses        |            | 11,648   |        | 0            |   | 11,648 |
| Interest                    |            | 0        |        | 9,535        |   | 9,535 |
| Miscellaneous               |            | 4,145    |        | 525          |   | 4,670 |
| Postage and delivery        |            | 0        |        | 44           |   | 44 |
| Professional fees           |            | 30,805   |        | 10,875       |   | 41,680 |
| Rent                        |            | 0        |        | 3,250        |   | 3,250 |
| Total expenses              | $               | 55,335   | $           | 142,699      | $ | 198,034 |
| Net income (loss)           | $               | (55,335) | $           | (142,699)    | $ | (198,034) |
| Net income (loss) per share | $               | (0.01)   | $           | (0.01)       | $ | (0.01 |
|                        |            |     |        |         |   |   |

|   | PRO FORMA CONSOLIDATED BALANCE SHEET |   |
|--------|--------------------------------------|--------|
|   | November 30, 2009                    |   |
|   | (Unaudited)                          |   |

|                                       |   | KUSHI RESOURCES |   | THERABIOGEN |   | CONSOLIDATED |
|--------------------------------------------|--------|-----------------|--------|-------------|--------|--------------|
| ASSETS                                     |   |            |   |        |   |         |
| Current assets                             |   |            |   |        |   |         |
| Cash                                       | $      |   1   | $      | 14,672      | $      | 14,673       |
| Other current assets                       |   |            |   |        |   |         |
|                                       |   |            |   |        |   |         |
| License, net of amortization               |   | 0               |   | 2,304,877   |   | 2,304,877    |
| Total current assets                       |   |  1         |   | 2,346,696   |   | 2,346,697    |
| TOTAL ASSETS                               | $      |  1         | $      | 2,346,696   | $      | 2,346,697    |
|                                       |   |            |   |        |   |         |
| LIABILITIES AND SHAREHOLDERS' EQUITY       |   |            |   |        |   |         |
| Current liabilities                        |   |            |   |        |   |         |
| Accounts payable and other                 |   | 47,378          |   | 11,710      |   | 59,088       |
| Other current liabilities                  |   |            |   |        |   |         |
| Accrued interest                           |   | 0               |   | 38,236      |   | 38,236       |
| Notes payable                              |   | 0               |   | 267,500     |   | 267,500      |
| Payroll taxes payable                      |   | 0               |   | 430         |   | 430          |
| Total current liabilities                  |   | 47,378          |   | 317,876     |   | 365,254      |
| Long-term liabilities                      |   | 0               |   | 310,000     |   | 310,000      |
| TOTAL LIABILITIES                          |   | 47,378          |   | 627,910     |   | 675,254      |
| Shareholders' equity (deficit)             |   |            |   |        |   |         |
| Common stock                               | $      | 5,230           | $      | 1,910       | $      | 32,689       |
| Additional paid-in capital                 |   | 51,270          |   | 2,375,785   |   | 2,401,506    |
| Accumulated deficit                        |   | (103,877)       |   | (658,875)   |   | (762,752)    |
| SHAREHOLDER'S EQUITY (DEFICIT)             |   | (47,377)        |   | 1,718,820   |   | 1,671,443    |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY |   | 70              |   | 2,346,696   |   | 2,346,697    |

----

| Kushi Resources | TheraBiogen |
|-----------------|-------------|

|                       |   | Pre-split |   | Post-split |   | Pre-merger |   | Post-merger |   | Consolidated |
|----------------------------|--------|-----------|--------|------------|--------|------------|--------|-------------|--------|--------------|
| Common Stock               |   | 5,230     |   | 13,598     |   | 1,910      |   | 19,091      |   | 32,689       |
| Additional paid-in capital |   | 51,270    |   | 42,902     |   | 2,375,785  |   | 2,358,604   |   | 2,401,506    |
| Accumulated deficit        |   | (103,877) |   | (103,877)  |   | (658,875)  |   | (658,875)   |   | (762,752)    |
| Shareholders' deficit      |   | (47,377)  |   | (47,377)   |   | 1,718,820  |   | 1,718,820   |   | 1,671,443    |

|                        | Kushi Resources |     | TheraBiogen | Consolidated |
|-----------------------------|-----------------|----------|-------------|--------------|
| Income                      | $               | 0        | $           | 0            | $ | 0 |
| Expenses:                   |            |     |        |         |   |   |
| Amortization                |            | 0        |        | 39,220       |   | 39,220 |
| Bank fees                   |            | 337      |        | 210          |   | 547 |
| Consulting                  |            | 8,400    |        | 79,040       |   | 87,440 |
| Exploration expenses        |            | 11,648   |        | 0            |   | 11,648 |
| Interest                    |            | 0        |        | 9,535        |   | 9,535 |
| Miscellaneous               |            | 4,145    |        | 525          |   | 4,670 |
| Postage and delivery        |            | 0        |        | 44           |   | 44 |
| Professional fees           |            | 30,805   |        | 10,875       |   | 41,680 |
| Rent                        |            | 0        |        | 3,250        |   | 3,250 |
| Total expenses              | $               | 55,335   | $           | 142,699      | $ | 198,034 |
| Net income (loss)           | $               | (55,335) | $           | (142,699)    | $ | (198,034) |
| Net income (loss) per share | $               | (0.01)   | $           | (0.01)       | $ | (0.01 |
|                        |            |     |        |         |   |   |

| ITEM 6. | EXHIBITS. |
|---------|-----------|

| Exhibit |                                                                                                                                                                           |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number  | Description of Exhibit                                                                                                                                                         |
|    |                                                                                                                                                                           |
| 3.1     | Articles of Incorporation.(1)                                                                                                                                                  |
|    |                                                                                                                                                                           |
|    |                                                                                                                                                                           |
|    |                                                                                                                                                                           |
|    |                                                                                                                                                                           |
| 3.1.1   | Amended Articles of Incorporation to change corporate name to TheraBiogen, Inc.                                                                                                |
| 3.2     | Bylaws.(1)                                                                                                                                                                     |
| 10.1    | Agreement and Plan of Merger with TheraBiogen, Inc. (2)                                                                                                                        |
| 14.1    | Code of Ethics.(1)                                                                                                                                                             |
| 14.2    | Code of Ethics, as amended.(3)                                                                                                                                                 |
| 31.1    | Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                                                |
| 32.1    | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |

|      |                                                                                                                                              |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------|
|  (1) | Previously filed as an Exhibit to our Registration Statement on Form SB-2, as amended, originally filed with the SEC on October 12, 2007.         |
|      |                                                                                                                                              |
|      |                                                                                                                                              |
|      |                                                                                                                                              |
|  (2) | Previously filed as an Exhibit to Form 8-K filed on November 18, 2009.                                                                            |
|  (3) | Previously filed as an exhibit to our Annual Report on Form 10-K for the fiscal year ended February 28, 2009 filed with the SEC on June 10, 2009. |

----

|   |                         |   |   | THERABIOGEN INC.                                          |
|--------|------------------------------|--------|--------|-----------------------------------------------------------|
|   |                         |   |   |                                                      |
| Date:  |   January 19, 2010 |   | By:    | /s/ Kelly T. Hickel                                       |
|   |                         |   |   | KELLY T. HICKEL                                           |
|   |                         |   |   | Chief Executive Officer, Chief Financial Officer          |
|   |                         |   |   | President, Secretary and Treasurer                        |
|   |                         |   |   | (Principal Executive Officer, Principal Financial Officer |

----